ReviewResearch (Washington, D.C.)2026
Metabolic Reprogramming and Immunometabolic Dysregulation in Diabetic Kidney Disease: From Pathogenesis to Precision Multi-target Therapies.
Ziyue Zhang, Yilun Qu, Xiaochen Wang, Yuwei Ji, Jin Yao, Weizhu Deng, Guannan Sun, Hua Xu, Xiangmei Chen, Quan Hong
Abstract readReview
In one paragraphReview in Research (Washington, D.C.), 2026. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Not yet cited in PubMed.
0numbers the graph read from it
0cells of the map it votes in
0citing papers in PubMed
–field-weighted citation impact
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
2 · The registryThe trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
3 · Its place in the literatureWho cites it
0 citing papers in PubMed.
No citing paper in PubMed yet.
4 · The recordCorrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
5 · Who and what moneyAuthors and funding
10 authors.
Ziyue ZhangDepartment of Nephrology, Chinese PLA General Hospital; Chinese PLA Institute of Nephrology; State Key Laboratory of Kidney Diseases; National Clinical Research Center of Kidney Diseases, Beijing 100853, China.ORCID https://orcid.org/0009-0002-2203-4693 Yilun QuDepartment of Nephrology, Chinese PLA General Hospital; Chinese PLA Institute of Nephrology; State Key Laboratory of Kidney Diseases; National Clinical Research Center of Kidney Diseases, Beijing 100853, China.
Xiaochen WangDepartment of Nephrology, Chinese PLA General Hospital; Chinese PLA Institute of Nephrology; State Key Laboratory of Kidney Diseases; National Clinical Research Center of Kidney Diseases, Beijing 100853, China.
Yuwei JiDepartment of Nephrology, Chinese PLA General Hospital; Chinese PLA Institute of Nephrology; State Key Laboratory of Kidney Diseases; National Clinical Research Center of Kidney Diseases, Beijing 100853, China.
Jin YaoDepartment of Nephrology, Chinese PLA General Hospital; Chinese PLA Institute of Nephrology; State Key Laboratory of Kidney Diseases; National Clinical Research Center of Kidney Diseases, Beijing 100853, China.
Weizhu DengDepartment of Nephrology, Chinese PLA General Hospital; Chinese PLA Institute of Nephrology; State Key Laboratory of Kidney Diseases; National Clinical Research Center of Kidney Diseases, Beijing 100853, China.
Guannan SunDepartment of Nephrology, Chinese PLA General Hospital; Chinese PLA Institute of Nephrology; State Key Laboratory of Kidney Diseases; National Clinical Research Center of Kidney Diseases, Beijing 100853, China.
Hua XuAcademy of Military Medical Sciences, Beijing 100850, China.
Xiangmei ChenDepartment of Nephrology, Chinese PLA General Hospital; Chinese PLA Institute of Nephrology; State Key Laboratory of Kidney Diseases; National Clinical Research Center of Kidney Diseases, Beijing 100853, China.ORCID https://orcid.org/0000-0001-8774-6021 Quan HongDepartment of Nephrology, Chinese PLA General Hospital; Chinese PLA Institute of Nephrology; State Key Laboratory of Kidney Diseases; National Clinical Research Center of Kidney Diseases, Beijing 100853, China.ORCID https://orcid.org/0000-0002-6839-7695 Funding
No grant is acknowledged in the PubMed record.
6 · The paper itselfAbstract
Diabetic kidney disease, the leading cause of end-stage kidney disease worldwide, involves complex interactions beyond classical hemodynamic and oxidative stress pathways. Recent advances emphasize metabolic reprogramming in renal cells-characterized by mitochondrial dysfunction, impaired fatty acid oxidation, lipotoxicity, and glycolytic shifts-as upstream drivers of cellular injury and fibrosis. Single-cell RNA sequencing reveals profound immunometabolic heterogeneity, including dynamic macrophage subpopulations (e.g., proinflammatory early states transitioning to TREM2
Identifiers
PMID42553440
PMCPMC13433925
What OpenQuestion holds
Textmetadata
LicenceCC BY
Read underepoch 390